ArticleArthritis research & therapy2017
VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes.
Article in Arthritis research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 55 citations in OpenAlex.
- Expression of VISTA on peripheral blood mononuclear cells in Systemic lupus erythematosus: association with disease activity and treatment status.Clinical and experimental medicine · 2026Article
- VISTA Deficiency Exacerbates Autoimmune Uveitis by Promoting Microglial Activation via the TLR4/MyD88/NF-κB Pathway.Investigative ophthalmology & visual science · 2026Article
- Immune checkpoint inhibitor-related arthritis and oral disorders: shared pathophysiology and clinical implications for rheumatology and oral health.Cancer cell international · 2025Review
- Macrophage-derived VISTA engages with LRIG1 and hinders gut epithelial repair in colitis.Cellular & molecular immunology · 2025Article
- The role of VISTA engagement in limiting neutrophil-mediated inflammation.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Immune Modulatory Effects of PD-1/PD-L1 in Myasthenia Gravis: Insights From Peripheral Blood Mononuclear Cell Analysis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Macrophages suppress CD8 + T cell cytotoxic function in triple negative breast cancer via VISTA.British journal of cancer · 2025Article
- Targeting cell-surface VISTA expression on allospecific naïve T cells promotes tolerance.Blood · 2025Article
- Therapeutic targeting of tumour-associated macrophage receptors.Immunotherapy advances · 2025Review
- Eliminating a barrier: Aiming at VISTA, reversing MDSC-mediated T cell suppression in the tumor microenvironment.Heliyon · 2024Review
- Single-cell RNA-Seq analysis reveals cell subsets and gene signatures associated with rheumatoid arthritis disease activity.JCI insight · 2024Article
- Repositioning baloxavir marboxil as VISTA agonist that ameliorates experimental asthma.Cell biology and toxicology · 2024Article
- Association Between VISTA and Vascular Cognitive Impairment in Older Chinese Adults: A Cross-Sectional Study.Clinical interventions in aging · 2024Article
- VISTA in hematological malignancies: a review of the literature.Frontiers in immunology · 2024Review
- VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy.Cancer cell international · 2023Review
- Therapy targeting antigen-specific T cells by a peptide-based tolerizing vaccine against autoimmune arthritis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance.Cancer immunology research · 2023Article
- PSGL-1: a novel immune checkpoint driving T-cell dysfunction in obstructive sleep apnea.Frontiers in immunology · 2023Article
- Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights.Frontiers in oncology · 2023Review
- Immune-checkpoint protein VISTA in allergic, autoimmune disease and transplant rejection.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundIn addition to activated T cells, the immune checkpoint inhibitor "V domain-containing Ig suppressor of T-cell activation" (VISTA) is expressed by myeloid cell types, including macrophages and neutrophils. The importance of VISTA expression by myeloid cells to antibody-induced arthritis and its potential for relevance in human disease was evaluated.
methodsVISTA was immunolocalized in normal and arthritic human synovial tissue sections and synovial tissue lysates were subjected to western blot analysis. The collagen antibody-induced arthritis model (CAIA) was performed with DBA/1 J mice treated with antibodies against VISTA and with VISTA-deficient mice (V-KO). Total mRNA from arthritic joints, spleens, and cultured macrophages was analyzed with NanoString arrays. Cytokines secreted by splenic inflammatory macrophages were determined. In-vitro chemotaxis and signal transduction assays were performed with cultured macrophages.
resultsVISTA protein was localized to synovial membrane cells, neutrophils, and scattered cells in lymphocyte-rich foci and was detected by western blot analysis in normal synovium and synovium from rheumatoid arthritis patients. Deficiency of VISTA or treatment of mice with anti-VISTA monoclonal antibodies attenuated CAIA. Joint damage and MMP-3 expression were significantly reduced in V-KO mice. Surface expression of C5a receptor was reduced on monocytes, neutrophils, and cultured macrophages from V-KO. Upon Fc receptor engagement in vitro, gene expression by V-KO macrophages was altered profoundly compared to WT, including a significant induction of IL-1 receptor antagonist (IL1rn).
conclusionsVISTA expression supports immune-complex inflammation in CAIA and VISTA is expressed in human synovium. VISTA supports optimal responses to C5a and modulates macrophage responses to immune complexes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.